NCT01921998

Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy

• Status: Suspended
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: The Christie NHS Foundation Trust · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Side effects from chemotherapy can be severe in some patients leading to admission to hospital, a worse quality of life and delays in subsequent doses of chemotherapy. A blood test that could predict patients who will go on to develop severe side effects could be useful and might allow early intervention with medicines to reduce the severity of the symptoms and prevent admission to hospital. This study will collect blood samples from patients with lymphoma or sarcoma who are receiving chemotherapy (with an expected admission rate for neutropenic sepsis, one of the side effects that most commonly results in hospital admission, of less than 20%). It will assess whether changes in blood proteins ("biomarkers") taken 2 days after the 1st chemotherapy can predict subsequent severe side effects throughout the 4 months of chemotherapy. In addition the investigators will collect data on quality of life and contact with medical professionals to assess the costs of chemotherapy toxicity to both the patient and health service. This will allow us in the future to model the cost effectiveness of using biomarkers in this manner to try and reduce chemotherapy toxicity.

Conditions

• Lymphoma
• Sarcoma

Interventions

Type	Name	Description
PROCEDURE	Biomarker and health economics	Biomarkers CK18 and FLT3 Ligand will be collected

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-11-01
• First posted: 2013-08-14
• Last updated: 2015-02-04

Locations

1 site across 1 country: United Kingdom